considered to be the most acceptable in this cohort, followed by mini-tablets. Chewable 37 tablets and granules were the least favoured. Consistently higher acceptability scores were 38 seen in the dysphagic population than in the non-dysphagic population for all of the dosage 39 forms that were easier to swallow than tablets and capsules. The development of these 40 formulations will assist in medication taking in older patients with dysphagia and potentially 41 their adherence to drug treatments. 
Introduction
Patient acceptability to a pharmaceutical dosage form is critical to ensure adherence and
5
The study was approved by the Ethics Committee of University of Hertfordshire
92
(LMS/SF/UH/00081) and was conducted at community pharmacies in the South East England 93 area in the UK during October to November 2014. A convenient sample of pharmacies was 94 recruited to participate in the study. The pharmacist in charge in each pharmacy was 95 informed the purpose of the study and approached consecutive patients attending the 96 pharmacy during week-day (Monday to Friday) opening hours who were eligible for the study.
97
The eligibility criteria include patients aged 65 years or over and prescribed at least one oral 98 medicine. No financial incentive was received by the pharmacies for participating in the study.
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Given the stated aims, the primary endpoint of the study was the proportion of primary care The third topic (7 items) assesses participants' acceptability of other alternative solid 137 medicine dosage forms to tablets and capsules, including mini-tablets, granules in a sachet, 138 dispersible/effervescent tablets, orally disintegrating tablets (ODTs) and chewable tablets.
7
These dosage forms are referred to as "alternative solid oral dosage forms" throughout this 140 article. The participants were shown samples of all formulation types and were given an 141 explanation of how the formulation should be administered. Mini-tablets were shown to 142 participants as mini-tablets filled in HGCs. Granules were presented as sprinkles onto food.
143
Dispersible tablets were presented as a drink with a minimum amount of 60 ml (or half a glass) 144 water required to dissolve the tablet. ODTs were described as melting/dissolving on the 145 tongue and chewable tablets were explained as needing to be chewed before swallowing.
146
They then provided their opinion on the formulation including past experience in using the 
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When a suitable commercial product was not identified to represent a formulation, placebo 179 samples were used (9 mm arched round tablets). The mean score for the self-perceived health status of all participants was 3.2 ± 1.1 (mean ± 207 SD, 1=excellent and 5=poor). There was a significant correlation between general health 208 status score and SSQ dysphagia score (r=0.250, p=0.002). The mean health status scores were 209 3.9 ±1.0 (mean ± SD) and 3.1 ±1.1 (mean ± SD) for participants with and without dysphagia 210 respectively. On average, the participants were prescribed 5.1 ± 3.8 (mean ± SD) oral solid presented, compared to only 6% in participants with dysphagia. In participants with 231 dysphagia, over a third (35%) selected size #00 as that which started to cause problems in 232 swallowing; however, around 30% of these participants also considered size #2 to be difficult 233 to swallow. Table 4 . 
Discussion
A range of medicine formulations have been made available for patients who find it difficult to swallow tablets and capsules. However, the acceptability of these formulations in targeted patient groups is often unclear. This pilot study is the first attempt to evaluate the acceptability of a range of solid oral dosage forms in older patients with and without dysphagia, using the newly developed Medicines Acceptability Questionnaire (MAQ). The content validity and reliability of the MAQ was established and the results of this study can be compared to future investigations. In our study, the prevalence of (symptoms compatible with) dysphagia in this older population attending community pharmacies was found to be 11%. This is in agreement with a study by Holland et al. in which 11.4% of participants of a community dwelling older population in England was found to have scores on the SSQ compatible with dysphagia (G. Holland et al., 2011) . This also broadly agrees with or is slightly lower than other published data on prevalence of dysphagia in older primary care patients (B.
R. Bloem et al., 1990 ; P. H. Chen et al., 2009; K. Kawashima et al., 2004) . In this study, age and gender of the participant did not significantly affect dysphagia score. Studies have reported that increasing age is associated with increased severity and prevalence of dysphagia in elderly populations (G. Holland et al., 2011; K. Kawashima et al., 2004) . However, Szcaesniak et al. studied SSQ score in a non-dysphagic population and found that there was no significant correlation between age and SSQ score (M. M. Szczesniak et al., 2014) . The majority of the participants in the current study were non-dysphagic, which might have contributed to the non-significant relationship between age and dysphagia score. It is also possible that the size of the cohort (n=156) was not large enough to see such an effect.
Almost half of participants took 5 or more solid oral medicines daily, which qualifies as polypharmacy by definition of some published studies (D. Gnjidic et al., 2012; U. JuniusWalker et al., 2007 ; D. Koper et al., 2013) . In addition, there was a significant relationship between dysphagia (SSQ) score and number of oral medicines taken on a daily basis. Marquis et al. did not find a significant relationship between difficulties in swallowing solid medicines and number of prescribed tablets among primary care adult patients who have at least 3 daily solid oral medications prescribed (J. Marquis et al., 2013) . Marquis et al. (2013) used patients' self-reported difficulties in swallowing solid medications instead of the validated questionnaire (SSQ) and this difference in methodology might have contributed to the deferring outcomes from the current study.
It has been documented that size and shape of tablets and capsules affect the "swallowability" and oesophageal transit in adults. Generally, difficulty in swallowing tablets increases with size (H. Hey et al., 1982; A. B. Overgaard et al., 2001 ). However, most of the published studies are conducted in healthy young subjects and limited information is available on the ability of older adults especially those with swallowing difficulties to swallow tablets and capsules. In the current study, participants with dysphagia (SSQ scores > 200) were more likely to have difficulties in swallowing tablets and capsules of the given sizes and shapes compared to non-dysphagic participants. Oblong and oval tablets were considered slightly easier to swallow than flat round and arched round tablets, which is in agreement with previous reports that large tablets of oblong and oval shapes are easier to swallow and pass esophagus faster than round tablets (K. S. Channer and J. P. Virjee, 1985; H. Hey et al., 1982; A. B. Overgaard et al., 2001) . Schiele et al. (2013) reported that round tablets of 8 mm in diameter started to cause swallowing difficulties in patients and for oval and oblong tablets the length of tablets reached 15 mm and 16 mm respectively to causing problem in swallowing (J. T. Schiele et al., 2013) .
Amongst the alternative solid oral dosage forms, dispersible/effervescent tablets ranked highest in acceptability score. Previous use of dispersible/effervescent tablets has the highest proportion of participants giving a positive response. A national survey across the UK showed that 90% of what was prescribed or sold over the counter to older people for long-term use which were regarded as being "easy to swallow" were effervescent tablets (W. Baqir and A. Maguire, 2000) . This familiarity with the type of the formulation and mode of administration might contribute to the high acceptance to these formulations.
ODTs and mini-tablets were also deemed acceptable in both the dysphagia and nondysphagia populations, following dispersible tablets. The main advantages of ODTs reported by the participants were convenient to use and easier to swallow. Indeed, previous work has indicated that ODTs require less effort to swallow than conventional tablets in patients with dysphagia (G. Carnaby-Mann and M. Crary, 2005) . The use of ODTs in older patients has been documented, especially in patients with Parkinson's and Alzheimer's diseases, and patients under antipsychotic treatments who might be purposely non-adherent (V. Danileviciute et al., 2009 ; B. J. Kinon et al., 2003; P. A. Nausieda, 2005) . The mini-tablets (4 mm in diameter) were considered easier to swallow than normal tablets due to small size by the participants. Minitablets (3 mm) were deemed appropriate for use in patients with Parkinson's disease, due to the potential of providing individualized dosage (S. Bredenberg et al., 2003) . However, concerns were raised in respect of difficulties in handling and seeing these smaller formulations by participants in our study and the study contacted by S. Bredenberg et al. (2003) . Future research is needed in investigating acceptability of mini-tables of smaller sizes, multiple dosages and the potential of using dispensing devices in older patients.
Chewable tablets and granules were considered as the least acceptable amongst the alternative dosage forms. Chewable tablets were useful in paediatric medicines for children over 2 years old (T. M. Michele et al., 2002) . However, they might not be appropriate for use in older patients, as there has been a reported decline in chewing ability in older age primarily due to tooth loss (I. A. Kida et al., 2007; P. Peltola and M. M. Vehkalahti, 2005) . Granules were not favored amongst the participants mostly due to reluctance in mixing medicines with food and concerns on incomplete dosing.
For all of the alternative solid dosage forms, consistently higher acceptability scores were seen in the dysphagia population than in the non-dysphagia population. Participants with dysphagia (SSQ scores > 200) are more likely to experience problems in taking their medicines in the form of tablets and capsules. The current study shows that formulation characteristics play a role in medicine acceptability in older patients. It is therefore important to make available a variety of formulation choices for older patients who find swallowing tablets and capsule difficult. The European Union legislation in paediatric medicines has prompt the development of formulations suitable for children (P. Kozarewicz, 2014) . The increasing availability of paediatric formulations could benefit older patients; however, there are distinct differences between the two populations (F. Liu et al., 2014) . Consequently, explicit considerations should be given to the older population to address their unique and specific needs in drug therapy and medicine use.
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The study has its limitations. The study recruited a convenient sample of community pharmacies which might introduce selection bias. The patients' self-reported difficulties in swallowing solid medicines were not compared with the current medications prescribed to the patients which might have correlated better with the types and characteristics of formulations that the patients can or cannot take. Diagrams of tablets of different sizes and shapes (except for 9 mm tablets) were presented instead of real samples which might affect participants' judgement in ability to swallow. The study focused on oral solid dosage forms and liquid medicines were not included. The need for liquid formulations might be higher in nursing homes and hospitals and these settings would be ideal to assess the acceptability to liquid medicines in future studies. The acceptance scores of the alternative dosage forms were not directly compared with that of tablets and capsules, which would be useful information for further investigation. Table 4 . Participants' impression on the flexible solid oral dosage forms. Mini-tablets  Small, easy to swallow
Conclusions

